002940.SZ
昂利康
SZSE · Healthcare · C 制造业 · CN
CNY 25.29
−4.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.4B | 1.5B | 1.6B | 1.6B |
| Cost of Revenue | 867.5M | 862.4M | 920.7M | 900.5M | 670.5M |
| Gross Profit | 551.9M | 562.4M | 617.2M | 725.4M | 897.9M |
| Operating Expenses | |||||
| R&D Expense | 126.4M | 144.1M | 214.3M | 143.4M | 112.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 78.8M | 79.9M | 92.4M | 103.0M | 72.6M |
| Selling & Marketing Expense | 172.4M | 171.5M | 181.6M | 293.0M | 559.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 396.1M | 412.0M | 493.8M | 547.0M | 747.4M |
| Cost and Expenses | 1.3B | 1.3B | 1.4B | 1.4B | 1.4B |
| Operating Income (EBIT) | 179.7M | 182.5M | 160.4M | 211.7M | 148.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 177.1M | 180.3M | 158.4M | 207.2M | 146.9M |
| Income Tax Expense | 22.8M | 23.5M | 6.5M | 24.1M | 15.0M |
| Bottom Line | |||||
| Net Income | 127.2M | 125.4M | 80.3M | 138.4M | 127.3M |
| Earnings from Cont. Ops | 154.4M | 156.7M | 151.9M | 183.1M | 132.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 127.2M | 125.4M | 80.3M | 138.4M | 127.3M |
| Per Share | |||||
| Basic EPS | CN¥0.64 | CN¥0.62 | CN¥0.40 | CN¥0.69 | CN¥0.64 |
| Diluted EPS | CN¥0.64 | CN¥0.62 | CN¥0.40 | CN¥0.69 | CN¥0.64 |
| Revenue Per Share | CN¥7.24 | CN¥7.04 | CN¥7.66 | CN¥8.11 | CN¥7.89 |
| Shares | |||||
| Basic Shares Outstanding | 196.2M | 202.3M | 200.8M | 200.5M | 198.9M |
| Diluted Shares Outstanding | 196.2M | 202.3M | 200.8M | 200.5M | 198.9M |
| Profitability Metrics | |||||
| EBITDA | — | 261.2M | 249.5M | 290.8M | 210.3M |
| D&A | — | 78.8M | 89.0M | 79.1M | 61.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026